设为首页  |   加入收藏

夏洪平


发布时间: 2017-10-23 访问次数: 13

   夏洪平,博士,江苏省特聘教授,博士生导师
  研究方向:基于分子病理的转化医学与精准治疗研究
  地址:江苏省南京市江宁区龙眠大道101号学海楼A522
  邮编:211166
  E-mail: xiahongping@njmu.edu.cn


个人简介:

夏洪平,男,医师/教授/博导,“国家青年千人”和“江苏省特聘教授”。2011年获香港大学博士学位,曾在维也纳医科大学癌症中心和新加坡国立癌症中心从事肿瘤分子病理,转化医学与精准治疗研究,已作为项目负责人(PI)主持新加坡国家医学研究委员会基金和保健服务集团基金及中国国自然基金多项,在Hepatology, Journal of Hepatology, ACS NanoACS Central Science等发表论著三十余篇,申请专利多项。目前担任国自然基金通讯评审,World Journal of Gastroenterology, Hepatoma ResearchGlioma等杂志编委和多个杂志审稿人。

  

社会兼职:

美国癌症协会会员;新加坡国立癌症中心青年科学家协会委员会;世界中医药学会联合会肿瘤精准医学专业委员会理事;World Journal of Gastroenterology, Hepatoma ResearchGlioma等杂志编委。

  

获奖情况

1. The Liver Week 2017,Incheon, Korea. Best Presentation Award.

2. SingHealth Publish! Award(Outstanding and )(20152016)

3. The 23rd Asia Pacific Cancer Conference,Bali,Indonesia (2015), Best oral presentation.

4. The 2012 International Society for Cell and Gene Therapy of Cancer Conference (ISCGT2012, Singapore), Beckman Poster Prize No.1

5.2012 “春晖杯”中国留学人员创新创业大赛优胜奖, 教育部国际合作与交流司.

6.2.Eurasia-Pacific Uninet Science and Technology Scholarships (the Republic of Austria, 2010)

  

承担课题:

1.国家“千人计划”青年项目,中组部,2018.1-2021.12

2. 江苏省特聘教授(2016特别优秀人才)项目,江苏省教育厅,2017.1-2019.12

3. 东南大学-南京医科大学合作研究项目(2017年重点项目)2018.1-2020.12

  

国家发明专利:

1.Profiling of hepatocellular carcinoma and applications thereof (PCT/SG2016/050221).

2.Hepatocellular carcinoma profiling and/or therapy (PCT/SG2015/050229).

近五年代表性论文:

(1)Xia H, Chen J, Shi M, Gao H, Sekar K, Seshachalam VP, Ooi LL, Hui KM. EDIL3 is a novel regulator of epithelial mesenchymal transition controlling early recurrence of hepatocellular carcinoma. J Hepatol. 2015 Oct; 63(4):863-73.

(2)Ling D*, Xia H*, et al. pH-Sensitive NanoformulatedTriptolide as a Targeted Therapeutic Strategy for Hepatocellular Carcinoma. ACS Nano. 2014 Aug 26;8(8):8027-39. (*Co-first author).

(3)Xia H, et al. MiR-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology. 2013 Aug; 58(2):629-41.

(4)Xia H, et al. pH-Sensitive Pt Nanocluster Assembly Overcomes CisplatinResistance and Heterogeneous Stemness of HepatocellularCarcinoma.ACS Cent. Sci., 2016, 2 (11), pp 802–811.

(5)Xia H, et al. MELK is an oncogenic kinase essential for early hepatocellular carcinoma recurrence.Cancer Lett. 2016 Dec 1;383(1):85-93.

(6)Chen J, Xia H, et al. ECT2 regulates the Rho/ERK signalling axis to promote early recurrence in human hepatocellular carcinoma.J Hepatol. 2015 Jun;62(6):1287-95.

(7)Chen J, MuthukumarRajasekaran, Xia H,….The microtubule-associated protein PRC1 promotes early recurrence of hepatocellular carcinoma in association with the Wnt/β-catenin signalling pathway. Gut. 2016 Sep;65(9):1522-34.

(8)Han J*, Xia H*, Wu Y, Kong SN, Deivasigamani A, Xu R, Hui KM, Kang Y.Single-layer MoS2 nanosheet grafted upconversion nanoparticles for near-infrared fluorescence imaging-guided deep tissue cancer phototherapy.Nanoscale. 2016 Apr 14;8(15):7861-5. (*Co-first author).

(9)Xia H, Hui KM.Emergence of aspirin as a promising chemopreventive and chemotherapeutic agent for liver cancer.Cell Death Dis. 2017 Oct 12;8(10):e3112.

(10)Xia H, Lee KW, Chen J, Kong SN, Sekar K, Deivasigamani A, Seshachalam VP, Goh BKP, Ooi LL, Hui KM.Simultaneous silencing of ACSL4 and induction of GADD45B in hepatocellular carcinoma cells amplifies the synergistic therapeutic effect of aspirin and sorafenib.Cell Death Discov. 2017 Sep 11;3:17058.

  版权所有© 南京医科大学基础医学院
  Tel:025-86869321 Fax:025-86869322